Business Context and Reporting Period
Transcode Therapeutics, Inc. (RNAZ) filed this Form 8-K on August 13, 2024, regarding its listing status on The Nasdaq Capital Market. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
- Stockholders' Equity: Reported at $1,322,274 as of June 30, 2024 (per Form 10-Q).
- Pro Forma Equity: Approximately $3.7 million as of June 30, 2024, assuming the inclusion of approximately $2.4 million in net proceeds from a July 2024 equity offering.
- Stock Price: Failed to maintain a minimum closing bid price of $1.00 per share for the 30 consecutive business days from July 1 through August 12, 2024.
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, profit, or cash flow for the current period.
Material Changes and Listing Deficiencies
The Company received two deficiency notices from Nasdaq:
- Minimum Bid Price Deficiency: The stock price remained below the $1.00 threshold for 30 consecutive days. Due to two reverse stock splits with a cumulative ratio exceeding 250:1 in the prior two years, the Company is ineligible for the standard 180-day compliance period.
- Stockholders' Equity Deficiency: The reported equity of $1,322,274 falls below the required $2,500,000 minimum. The Company does not meet alternative quantitative standards (market value of listed securities of $35 million or net income of $500,000).
Outlook, Risks, and Management Commentary
Management intends to timely request a hearing before a Nasdaq Hearings Panel to address the Minimum Bid Price deficiency. This request will automatically stay any suspension or delisting action pending the hearing. However, there is no assurance that the Panel will grant an extension or that the Company will regain compliance. The Stockholders' Equity deficiency serves as an additional basis for potential delisting and will be considered during the hearing. The Company has not yet requested a hearing regarding the equity deficiency but may do so by August 22, 2024, if the bid price issue is resolved.
Investor Verification Checklist
- Confirm the status of the hearing request with the Nasdaq Hearings Panel.
- Verify if the July 2024 equity offering proceeds are recognized in the most recent audited financial statements for the equity requirement.
- Monitor the daily closing bid price to determine if the $1.00 threshold is met.
- Review the Company's Form 10-Q for the period ended June 30, 2024, for detailed financial condition and liquidity risks.